Moderna’s $2.8 Billion Loss Contrasts With Vertex’s $4 — JournalArta Global
Moderna reported a net loss of $2.8B and revenue of $1.9B for FY 2025, with a 39.2% revenue decline due to reduced COVID-19 product demand. Vertex Pharmaceuticals reported a net income of $4B and revenue of $12.1B, with a 9.6% revenue growth. Both companies face distinct business risks and financial profiles.
How this was made
The 30-second read
Why it matters
Moderna's deep loss may pressure its share price, while Vertex's strong earnings could buoy its stock, underscoring divergent trajectories in biotech.
Market read
The contrasting results provide a clear signal for sector rotation between vaccine‑centric and specialty‑drug biotech stocks.
What to watch
Vertex's reliance on cystic fibrosis drugs introduces concentration risk despite current profitability.
Background
The article compares FY 2025 financial outcomes for Moderna and Vertex, emphasizing the stark contrast in profitability.
Ticker impact
Moderna reported a FY 2025 net loss of about $2.8 billion and a 39% revenue decline.
likely downside as investors price in weaker earnings and cash flow.
First‑time disclosure of FY 2025 results showing deep losses and negative free cash flow.
Vertex posted FY 2025 revenue of $12.1 billion and net income of roughly $4 billion.
potential upside as investors view the earnings as a contrast to peers.
First‑time disclosure of FY 2025 results highlighting robust profitability.
Market effects
Highlights divergence within biotech, with vaccine‑focused firms under pressure versus specialty‑drug companies.
U.S. biotech sector may see mixed moves as investors re‑price earnings variance.
Limited to investors tracking large‑cap biotech earnings; no broader macro impact.
Counterpoint
Moderna's loss could be a buying opportunity if its mRNA pipeline later drives growth.
Key entities
- companyModerna
Biotech firm focused on mRNA vaccines, reporting FY 2025 loss.
- companyVertex Pharmaceuticals
Biotech firm specializing in cystic fibrosis treatments, reporting FY 2025 profit.
